SECsense Logo

Inmune Bio Inc. Reports Major Update in Form 8-K - February 12, 2025

$INMB
Form 8-K
Filed on: 2025-02-12
Source
Inmune Bio Inc. Reports Major Update in Form 8-K - February 12, 2025

Here are the key pieces of information extracted from the provided section of the financial report:

  1. Document Type: Form 8-K
  • Filing Date: February 12, 2025
  1. Company Information:
  • Name: Inmune Bio Inc.
  • CIK: 0001711754
  • SEC File Number: 001-38793
  • Employer Identification Number (EIN): 47-5205835
  • Address: 225 NE Mizner Blvd., Suite 640, Boca Raton, FL 33432
  • Phone Number: 858-964-3720
  • Trading Symbol: INMB
  • Exchange: NASDAQ
  1. Reporting Date: The report pertains to a specific date, February 12, 2025.
  2. Stock Information:
  • Common Stock with a par value of $0.001 per share.
  1. Units of Measurement:
  • Financial figures are reported in U.S. Dollars (USD) and in terms of shares.
  1. Context and Structure:
  • The document is structured using XBRL (eXtensible Business Reporting Language), which is common for SEC filings to allow for easier data extraction and analysis.

Insights:

  • The filing is a Form 8-K, which is typically used to report major events that shareholders should know about, indicating that Inmune Bio Inc. likely experienced or announced a significant development on or before February 12, 2025.
  • The presence of the company's trading details suggests that it is publicly traded, which can have implications for investor relations and market perception.
  • The par value of the common stock is relatively low, which is often indicative of many biotech or startup companies that may issue shares at lower par values to facilitate capital raising without significant dilution.

This information is crucial for stakeholders (investors, analysts) to understand the business context, assess the company's market position, and evaluate any significant developments reported in the 8-K.